
    
      A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib +
      Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with
      Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast
      Cancer (TNBC)
    
  